darolutamide
FDA Approves Nubeqa for Metastatic Castration-Sensitive Prostate Cancer
The FDA has approved darolutamide (Nubeqa, Bayer) for metastatic castration-sensitive prostate cancer ...
JUNE 3, 2025
New Approval for Darolutamide
The FDA approved an additional indication of darolutamide (Nubeqa, Bayer) in combination with docetaxel for the ...
AUGUST 18, 2022
Darolutamide Triplet Therapy Improves Survival In mHSPC
Adding the androgen receptor inhibitor darolutamide (Nubeqa, Bayer/Orion) to androgen deprivation therapy (ADT) and ...
APRIL 12, 2022
Darolutamide Shows Promise for Treatment of nmCRPC
The just-approved androgen receptor inhibitor darolutamide is poised to shake up the treatment paradigm for men ...
JULY 26, 2019
Load more